OKYO Pharma Ltd
OKYO Pharma Ltd (OKYO): 2 pipeline candidates · 1 clinical trial. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for OKYO Pharma Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$82.4M
Cash
$4.6M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ok-101 0.05% | Phase 2 |
| ok-101 0.1% | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$2.9M
| Holder | Shares | Value |
|---|---|---|
| maven securities ltd | 1,175,535 | $1.9M |
| balyasny asset management l.p. | 584,796 | $942K |
| xtx topco ltd | 37,652 | $61K |
| geode capital management, llc | 12,090 | $19K |
| osaic holdings, inc. | 152 | $244 |
| morgan stanley | 10 | $16 |
Frequently asked questions
How many drug candidates are in OKYO Pharma Ltd's pipeline?
OKYO Pharma Ltd (OKYO) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OKYO Pharma Ltd's lead drug candidate?
OKYO Pharma Ltd's most advanced tracked candidate is ok-101 0.05% (Phase 2) for Neuropathic Pain.
What is OKYO Pharma Ltd's market capitalization?
OKYO Pharma Ltd's market capitalization is approximately $82.4M.
Who is the CEO of OKYO Pharma Ltd?
Mr. Robert J. Dempsey M.B.A. is the chief executive officer of OKYO Pharma Ltd (OKYO).
Get the full picture on OKYO Pharma Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.